Monitor YARTEMLEA prescription trends for Q2 and the EMA decision on TA-TMA approval expected mid-2026. NTAP final rule in August could further boost hospital demand.
OMER drugs
OMER drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 14 $13.28entry
- T+1 · 6mo ago 0.00%α −0.01% · $13.28
- T+5 · 6mo ago −9.94%α −9.22% · $11.96
- T+20 · 5mo ago −34.19%α −33.33% · $8.74
- T+60 · 3mo ago +2.56%α −1.03% · $13.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Omeros reported Q1 2026 results with first-ever YARTEMLEA commercial sales of $9.9M net, GAAP net income of $56.1M (vs a $33.5M loss a year ago), and non-GAAP adjusted net loss of $17.1M ($0.24/share) that beat consensus of -$0.28. Revenue slightly missed $10.1M consensus. CMS assigned a J-code effective July 1 and recommended NTAP, signaling improving reimbursement.
Key Financial Metrics
Key Facts
- First YARTEMLEA net sales of $9.9M in Q1 2026 (launched Jan 2026)
- GAAP net income $56.1M vs net loss of $33.5M in Q1 2025
- Non-GAAP adjusted net loss $17.1M ($0.24/share) beat consensus $-0.28
- Revenue $9.9M vs consensus $10.1M (miss of ~2%)
- CMS assigned permanent J-code for YARTEMLEA (effective July 1) and recommended NTAP
- Cash and short-term investments $135.3M at March 31; only $70.8M debt remaining (2029 Notes)
- Repurchased 0.4M shares for $4.2M during Q1
Financial Impact
First commercial YARTEMLEA sales of $9.9M; non-GAAP EPS beat consensus by 14%
Risk Factors
- YARTEMLEA adoption may slow without broader label or EU approval
- Non-GAAP adjusted operations still unprofitable; cash burn continues
- Revenue miss could pressure near-term expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-016718 |
| Document: omer20260403_8k.htm | 0001437749-26-016718 |
| Document: 0001437749-26-016718-index-headers.html | 0001437749-26-016718 |
| Document: 0001437749-26-016718-index.html | 0001437749-26-016718 |
| Document: 0001437749-26-016718.txt | 0001437749-26-016718 |
| 8-K Data (Synthetic) | 0001437749-26-016718 |
Track record
12 reports on OMER
2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +98.11% at T+60 after the Jul 20, 2026 report. 3 of 3 went positive at some point.
Filters
- Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $16.92 Now $16.68 −1.42% settles Feb 4
- Oct 30, 202617d ago 8-K Neutral 3/10 Entry $17.83 Now $16.68 −6.45% settles Jan 29
- Sep 1, 202610w ago Insider Cluster Neutral 2/10 Entry $18.86 Now $16.68 −11.56% settles Nov 27
- Aug 28, 202611w ago Insider Cluster Neutral Not scored Entry $18.79 Now $16.68 −11.23% settles Nov 24
- Aug 25, 202611w ago Insider Cluster Neutral 3/10 Entry $18.22 Now $16.68 −8.45% settles Nov 19
- Aug 21, 202612w ago Insider Cluster Neutral 2/10 Entry $19.32 Now $16.68 −13.66% settles Nov 17
- Jul 20, 202617w ago 8-K Bullish 5/10 Entry $9.53 to $18.88 Now $16.68 +75.03% ▲ +98.11% +94.14% vs SPY
- Jul 6, 202619w ago 8-K Neutral 4/10 Entry $10.34 to $19.25 Now $16.68 +61.32% ▲ +86.17% +84.45% vs SPY
- Jun 18, 202621w ago 8-K Bullish 5/10 Entry $10.28 to $17.46 Now $16.68 +62.26% ▲ +69.84% +67.95% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 4/10 Entry $10.18 to $18.95 Now $16.68 +63.85% ▲ +86.15% +81.75% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers